Najat Khan - Feb 3, 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief R&D Commercial Officer, Director
Signature
/s/ Kyle Nelson, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Feb 3, 2025
Transactions value $
-$19,959
Form type
4
Date filed
2/5/2025, 04:50 PM
Previous filing
Aug 5, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +210K +42.28% $0.00 707K Feb 3, 2025 Direct F1
transaction RXRX Class A Common Stock Award $0 +8.05K +1.14% $0.00 715K Feb 3, 2025 Direct F2
transaction RXRX Class A Common Stock Tax liability -$20K -2.75K -0.38% $7.25 712K Feb 3, 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Award $0 +420K $0.00 420K Feb 3, 2025 Class A Common Stock 420K $7.25 Direct F4
holding RXRX Stock Option (Right to Buy) 994K Feb 3, 2025 Class A Common Stock 0 $7.34 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2025 and every three months thereafter.
F2 This RSU vested immediately upon the grant date.
F3 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F4 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F5 This option vests as to one fourth (1/4th) of the shares subject to the option on July 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date.